Top

Published in:

01-09-2008 | Research Paper

Decreased adhesiveness, resistance to anoikis and suppression of GRP94 are integral to the survival of circulating tumor cells in prostate cancer

Authors: Edward W. Howard, Steve C. L. Leung, H. F. Yuen, Chee Wai Chua, Davy T. Lee, K. W. Chan, Xianghong Wang, Yong Chuan Wong

Published in: Clinical & Experimental Metastasis | Issue 5/2008

Abstract

The presence of circulating tumor cells (CTC) is common in prostate cancer patients, however until recently their clinical significance was unknown. The CTC stage is essential for the formation of distant metastases, and their continuing presence after radical prostatectomy has been shown to predict recurrent or latent disease. Despite their mechanistic and prognostic importance, due both to their scarcity and difficulties in their isolation, little is known about the characteristics that enable their production and survival. The aim of this study was to investigate the molecular mechanisms underlying the survival of CTC cells. A novel CTC cell line from the bloodstream of an orthotopic mouse model of castration-resistant prostate cancer was established and compared with the primary tumor using attachment assays, detachment culture, Western blot, flow cytometry and 2D gel electrophoresis. Decreased adhesiveness and expression of adhesion molecules E-cadherin, β4-integrin and γ-catenin, together with resistance to detachment and drug-induced apoptosis and upregulation of Bcl-2 were integral to the development of CTC and their survival. Using proteomic studies, we observed that the GRP94 glycoprotein was suppressed in CTC. GRP94 was also shown to be suppressed in a tissue microarray study of 79 prostate cancer patients, indicating its possible role in prostate cancer progression. Overall, this study suggests molecular alterations accounting for the release and survival of CTC, which may be used as drug targets for either anti-metastatic therapy or the suppression of latent disease. We also indicate the novel involvement of GRP94 suppression in prostate cancer metastasis.

Marugame T, Mizuno S (2005) Comparison of prostate cancer mortality in five countries: France, Italy, Japan, UK and USA from the WHO mortality database (1960–2000). Jpn J Clin Oncol 35:690–691PubMedCrossRef

Albertsen PC, Hanley JA, Penson DF, Barrows G, Fine J (2007) 13-year outcomes following treatment for clinically localized prostate cancer in a population based cohort. J Urol 177:932–936PubMedCrossRef

Mocellin S, Keilholz U, Rossi CR, Nitti D (2006) Circulating tumor cells: the ‘leukemic phase’ of solid cancers. Trends Mol Med 12:130–139PubMedCrossRef

Morgan TM, Lange PH, Vessella RL (2007) Detection and characterization of circulating and disseminated prostate cancer cells. Front Biosci 12:3000–3009PubMedCrossRef

Sheu CC, Yu YP, Tsai JR, Chang MY, Lin SR, Hwang JJ, Chong IW (2006) Development of a membrane array-based multimarker assay for detection of circulating cancer cells in patients with non-small cell lung cancer. Int J Cancer 119:1419–1426PubMedCrossRef

Riethdorf S, Fritsche H, Muller V, Rau T, Schindlbeck C, Rack B, Janni W, Coith C, Beck K, Janicke F, Jackson S, Gornet T, Cristofanilli M, Pantel K (2007) Detection of circulating tumor cells in peripheral blood of patients with metastatic breast cancer: a validation study of the CellSearch system. Clin Cancer Res 13:920–928PubMedCrossRef

Wang JY, Wu CH, Lu CY, Hsieh JS, Wu DC, Huang SY, Lin SR (2006) Molecular detection of circulating tumor cells in the peripheral blood of patients with colorectal cancer using RT-PCR: significance of the prediction of postoperative metastasis. World J Surg 30:1007–1013PubMedCrossRef

Liu Z, Jiang M, Zhao J, Ju H (2007) Circulating tumor cells in perioperative esophageal cancer patients: quantitative assay system and potential clinical utility. Clin Cancer Res 13:2992–2997PubMedCrossRef

Danila DC, Heller G, Gignac GA, Gonzalez-Espinoza R, Anand A, Tanaka E, Lilja H, Schwartz L, Larson S, Fleisher M, Scher HI (2007) Circulating tumor cell number and prognosis in progressive castration-resistant prostate cancer. Clin Cancer Res 13:7053–7058PubMedCrossRef

10.

Garcia JA, Rosenberg JE, Weinberg V, Scott J, Frohlich M, Park JW, Small EJ (2007) Evaluation and significance of circulating epithelial cells in patients with hormone-refractory prostate cancer. BJU Int 99:519–524PubMedCrossRef

11.

Berg A, Berner A, Lilleby W, Bruland OS, Fossa SD, Nesland JM, Kvalheim G (2007) Impact of disseminated tumor cells in bone marrow at diagnosis in patients with nonmetastatic prostate cancer treated by definitive radiotherapy. Int J Cancer 120:1603–1609PubMedCrossRef

12.

Moreno JG, Miller MC, Gross S, Allard WJ, Gomella LG, Terstappen LW (2005) Circulating tumor cells predict survival in patients with metastatic prostate cancer. Urology 65:713–718PubMedCrossRef

13.

Schamhart DH, Maiazza R, Kurth KH (2005) Identification of circulating prostate cancer cells: a challenge to the clinical implementation of molecular biology (review). Int J Oncol 26:565–577PubMed

14.

Howard EW, Ling MT, Chua CW, Cheung HW, Wang X, Wong YC (2007) Garlic-derived S-allylmercaptocysteine is a novel in vivo antimetastatic agent for androgen-independent prostate cancer. Clin Cancer Res 13:1847–1856PubMedCrossRef

15.

Posadas EM, Gulley J, Arlen PM, Trout A, Parnes HL, Wright J, Lee MJ, Chung EJ, Trepel JB, Sparreboom A, Chen C, Jones E, Steinberg SM, Daniels A, Figg WD, Dahut WL (2005) A phase II study of perifosine in androgen independent prostate cancer. Cancer Biol Ther 4:1133–1137PubMedCrossRef

16.

Iinuma H, Okinaga K, Egami H, Mimori K, Hayashi N, Nishida K, Adachi M, Mori M, Sasako M (2006) Usefulness and clinical significance of quantitative real-time RT-PCR to detect isolated tumor cells in the peripheral blood and tumor drainage blood of patients with colorectal cancer. Int J Oncol 28:297–306PubMed

17.

Moreno JG, O’Hara SM, Gross S, Doyle G, Fritsche H, Gomella LG, Terstappen LW (2001) Changes in circulating carcinoma cells in patients with metastatic prostate cancer correlate with disease status. Urology 58:386–392PubMedCrossRef

18.

Condeelis JS, Wyckoff J, Segall JE (2000) Imaging of cancer invasion and metastasis using green fluorescent protein. Eur J Cancer 36:1671–1680PubMedCrossRef

19.

Ma S, Guan XY, Beh PS, Wong KY, Chan YP, Yuen HF, Vielkind J, Chan KW (2007) The significance of LMO2 expression in the progression of prostate cancer. J Pathol 211:278–285PubMedCrossRef

20.

Yuen HF, Chua CW, Chan YP, Wong YC, Wang X, Chan KW (2006) Id proteins expression in prostate cancer: high-level expression of Id-4 in primary prostate cancer is associated with development of metastases. Mod Pathol 19:931–941PubMedCrossRef

21.

Foty RA, Steinberg MS (2004) Cadherin-mediated cell-cell adhesion and tissue segregation in relation to malignancy. Int J Dev Biol 48:397–409PubMedCrossRef

22.

Slack-Davis JK, Parsons JT (2004) Emerging views of integrin signaling: implications for prostate cancer. J Cell Biochem 91:41–46PubMedCrossRef

23.

Cress AE, Rabinovitz I, Zhu W, Nagle RB (1995) The alpha 6 beta 1 and alpha 6 beta 4 integrins in human prostate cancer progression. Cancer Metastasis Rev 14:219–228PubMedCrossRef

24.

Umbas R, Isaacs WB, Bringuier PP, Schaafsma HE, Karthaus HF, Oosterhof GO, Debruyne FM, Schalken JA (1994) Decreased E-cadherin expression is associated with poor prognosis in patients with prostate cancer. Cancer Res 54:3929–3933PubMed

25.

Tran NL, Nagle RB, Cress AE, Heimark RL (1999) N-Cadherin expression in human prostate carcinoma cell lines. An epithelial-mesenchymal transformation mediating adhesion with stromal cells. Am J Pathol 155:787–798PubMed

26.

Berezovskaya O, Schimmer AD, Glinskii AB, Pinilla C, Hoffman RM, Reed JC, Glinsky GV (2005) Increased expression of apoptosis inhibitor protein XIAP contributes to anoikis resistance of circulating human prostate cancer metastasis precursor cells. Cancer Res 65:2378–2386PubMedCrossRef

27.

Fu Y, Lee AS (2006) Glucose regulated proteins in cancer progression, drug resistance and immunotherapy. Cancer Biol Ther 5:741–744PubMed

28.

Chen X, Ding Y, Liu CG, Mikhail S, Yang CS (2002) Overexpression of glucose-regulated protein 94 (Grp94) in esophageal adenocarcinomas of a rat surgical model and humans. Carcinogenesis 23:123–130PubMedCrossRef

29.

Wang XP, Qiu FR, Liu GZ, Chen RF (2005) Correlation between clinicopathology and expression of heat shock protein 70 and glucose-regulated protein 94 in human colonic adenocarcinoma. World J Gastroenterol 11:1056–1059PubMed

30.

Luo J, Lubaroff DM, Hendrix MJ (1999) Suppression of prostate cancer invasive potential and matrix metalloproteinase activity by E-cadherin transfection. Cancer Res 59:3552–3556PubMed

31.

Morita N, Uemura H, Tsumatani K, Cho M, Hirao Y, Okajima E, Konishi N, Hiasa Y (1999) E-cadherin and alpha-, beta- and gamma-catenin expression in prostate cancers: correlation with tumour invasion. Br J Cancer 79:1879–1883PubMedCrossRef

32.

Mehes G, Witt A, Kubista E, Ambros PF (2001) Circulating breast cancer cells are frequently apoptotic. Am J Pathol 159:17–20PubMed

33.

Fernandez Y, Gu B, Martinez A, Torregrosa A, Sierra A (2002) Inhibition of apoptosis in human breast cancer cells: role in tumor progression to the metastatic state. Int J Cancer 101:317–326PubMedCrossRef

34.

Zellweger T, Ninck C, Bloch M, Mirlacher M, Koivisto PA, Helin HJ, Mihatsch MJ, Gasser TC, Bubendorf L (2005) Expression patterns of potential therapeutic targets in prostate cancer. Int J Cancer 113:619–628PubMedCrossRef

35.

Tran NL, Adams DG, Vaillancourt RR, Heimark RL (2002) Signal transduction from N-cadherin increases Bcl-2. Regulation of the phosphatidylinositol 3-kinase/Akt pathway by homophilic adhesion and actin cytoskeletal organization. J Biol Chem 277:32905–32914PubMedCrossRef

36.

Coll ML, Rosen K, Ladeda V, Filmus J (2002) Increased Bcl-xL expression mediates v-Src-induced resistance to anoikis in intestinal epithelial cells. Oncogene 21:2908–2913PubMedCrossRef

37.

Liu AX, Jin F, Zhang WW, Zhou TH, Zhou CY, Yao WM, Qian YL, Huang HF (2006) Proteomic analysis on the alteration of protein expression in the placental villous tissue of early pregnancy loss. Biol Reprod 75:414–420PubMedCrossRef

38.

Vawter MP, Crook JM, Hyde TM, Kleinman JE, Weinberger DR, Becker KG, Freed WJ (2002) Microarray analysis of gene expression in the prefrontal cortex in schizophrenia: a preliminary study. Schizophr Res 58:11–20PubMedCrossRef

39.

Cheng Q, Lau WM, Tay SK, Chew SH, Ho TH, Hui KM (2002) Identification and characterization of genes involved in the carcinogenesis of human squamous cell cervical carcinoma. Int J Cancer 98:419–426PubMedCrossRef

40.

Kubota H, Suzuki T, Lu J, Takahashi S, Sugita K, Sekiya S, Suzuki N (2005) Increased expression of GRP94 protein is associated with decreased sensitivity to X-rays in cervical cancer cell lines. Int J Radiat Biol 81:701–709PubMedCrossRef

41.

Lee AS (2001) The glucose-regulated proteins: stress induction and clinical applications. Trends Biochem Sci 26:504–510PubMedCrossRef

42.

Reddy RK, Dubeau L, Kleiner H, Parr T, Nichols P, Ko B, Dong D, Ko H, Mao C, DiGiovanni J, Lee AS (2002) Cancer-inducible transgene expression by the Grp94 promoter: spontaneous activation in tumors of various origins and cancer-associated macrophages. Cancer Res 62:7207–7212PubMed

43.

Korbelik M, Sun J, Cecic I (2005) Photodynamic therapy-induced cell surface expression and release of heat shock proteins: relevance for tumor response. Cancer Res 65:1018–1026PubMed

44.

Takagi S, Miyagawa S, Ichikawa E, Soeda J, Miwa S, Miyagawa Y, Iijima S, Noike T, Kobayashi A, Kawasaki S (2004) Dendritic cells, T-cell infiltration, and Grp94 expression in cholangiocellular carcinoma. Hum Pathol 35:881–886PubMedCrossRef

45.

Baker-LePain JC, Sarzotti M, Fields TA, Li CY, Nicchitta CV (2002) GRP94 (gp96) and GRP94 N-terminal geldanamycin binding domain elicit tissue nonrestricted tumor suppression. J Exp Med 196:1447–1459PubMedCrossRef

46.

Gastpar R, Gehrmann M, Bausero MA, Asea A, Gross C, Schroeder JA, Multhoff G (2005) Heat shock protein 70 surface-positive tumor exosomes stimulate migratory and cytolytic activity of natural killer cells. Cancer Res 65:5238–5247PubMedCrossRef

47.

Yang Q, Goding SR, Hokland ME, Basse PH (2006) Antitumor activity of NK cells. Immunol Res 36:13–25PubMedCrossRef

48.

Bastide C, Bagnis C, Mannoni P, Hassoun J, Bladou F (2002) A Nod Scid mouse model to study human prostate cancer. Prostate Cancer Prostatic Dis 5:311–315PubMedCrossRef

49.

Wang Q, He Z, Zhang J, Wang Y, Wang T, Tong S, Wang L, Wang S, Chen Y (2005) Overexpression of endoplasmic reticulum molecular chaperone GRP94 and GRP78 in human lung cancer tissues and its significance. Cancer Detect Prev 29:544–551PubMedCrossRef

50.

Wang XP, Liu GZ, Song AL, Chen RF, Li HY, Liu Y (2005) Expression and significance of heat shock protein 70 and glucose-regulated protein 94 in human esophageal carcinoma. World J Gastroenterol 11:429–432PubMed

51.

Wang XP, Liao J, Liu GZ, Wang XC, Shang HW (2005) Co-expression of heat shock protein 70 and glucose-regulated protein 94 in human gastric carcinoma cell line BGC-823. World J Gastroenterol 11:3601–3604PubMed

Title: Decreased adhesiveness, resistance to anoikis and suppression of GRP94 are integral to the survival of circulating tumor cells in prostate cancer
Authors: Edward W. Howard
Steve C. L. Leung
H. F. Yuen
Chee Wai Chua
Davy T. Lee
K. W. Chan
Xianghong Wang
Yong Chuan Wong
Publication date: 01-09-2008
Publisher: Springer Netherlands
Published in: Clinical & Experimental Metastasis / Issue 5/2008
Print ISSN: 0262-0898
Electronic ISSN: 1573-7276
DOI: https://doi.org/10.1007/s10585-008-9157-3

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 5/2008

Rho GTPases in PC-3 prostate cancer cell morphology, invasion and tumor cell diapedesis

Bone resorption increases tumour growth in a mouse model of osteosclerotic breast cancer metastasis

A highly bone marrow metastatic murine breast cancer model established through in vivo selection exhibits enhanced anchorage-independent growth and cell migration mediated by ICAM-1

Intraosseous injection of RM1 murine prostate cancer cells promotes rapid osteolysis and periosteal bone deposition

TM4SF3 promotes esophageal carcinoma metastasis via upregulating ADAM12m expression

Single-cell tumor dormancy model of uveal melanoma

Keynote webinar | Spotlight on antibody–drug conjugates in cancer